For the average clinical lab director, cascade testing has always been a logistical nightmare. When a patient tests positive for a germline mutation, the lab’s technical work is done, but the clinical utility remains locked behind the patient’s ability—or willingness—to notify their relatives.
A new study out of the University of Michigan’s Rogel Cancer Center, published in the Journal of Clinical Oncology, claims to have found a solution: a web-based portal called GIFT (Genetic Information and Family Testing).
But while researchers are touting the efficiency of an online-only model, a closer look at the data suggests that automating the family tree might be harder than a simple UI update.
The efficiency claim vs. the reality
The trial tracked 414 cancer survivors who carried pathogenic variants. The goal was to see if a web portal could replace human care teams in convincing relatives to get tested. The results were not good for the web portal:
- Low invitation rates: Only 20% of patients actually used the tool to invite their family members.
- Low enrollment: Of those invited, only 33% bothered to log in.
- The price wall: Even at a heavily subsidized rate of $50, testing uptake dropped significantly compared to free tests.
Researchers will introduce a chatbot as the next step
Despite the lukewarm engagement, the Michigan team is moving forward with a second iteration that replaces human interaction with an AI assistant. The goal is to personalize genetic risk information and facilitate difficult family conversations via chatbot.
For lab professionals, this raises a red flag. Genetic testing involves complex interpretation and potential psychological fallout for relatives of patients. Steven J. Katz, MD, MPH, a researcher at the Rogel Cancer Center, noted the unique nature of these results. “Few medical tests have implications for others beyond the patient,” Katz told the University of Michigan’s Health Lab. “But with germline genetic testing, the results can be very significant to the health of others around you.”
If 80% of patients aren't even willing to click a link to help their siblings, it is worth asking if the "unmet need" is a lack of technology or a fundamental human reluctance that a chatbot cannot fix.
Cascade testing factors for clinical labs to consider
The University of Michigan estimates that more than 250,000 cancer patients in the US will undergo genetic testing in 2026. The pressure to provide further information for families is shifting from the clinic to the digital space. For laboratories, this trend suggests a future where:
- Margin pressure: The study proves that unless testing is free, relatives won't do it. This puts the financial burden of cascade testing back on labs or health systems to find subsidies.
- Automation bias: By removing a human element from cascade testing, the healthcare industry is betting that software can handle some of the nuances of genetic counseling.
The skeptic’s corner
While Katz framed the GIFT study as a "promising blueprint," clinical lab managers and pathologists would do well to maintain a healthy dose of skepticism. A controlled trial involving 414 participants is a sterile environment that rarely accounts for the messy reality of family estrangement, health literacy barriers, or people simply ignoring notifications sent to their phones or inboxes.
For the clinical lab, the ultimate question isn't whether the software works; it’s whether GIFT results in a meaningful increase in clinical volume or just more sophisticated data that relatives of cancer patients don’t act upon.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
